SCHEMBL3488988

SCHEMBL3488988

Cc1ccccc1CNS(=O)(=O)c1c(N)cc(Cl)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
NR3C1 P04150 6/20 0.47
NR3C2 P08235 6/20 0.47
PGR P06401 3/20 0.47
CYP3A4 P08684 3/20 0.47
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HPGD P15428 3/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPK1 P28482 1/20 0.40
AKR1B1 P15121 1/20 0.40
POLB P06746 1/20 0.40
TP53 P04637 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ACLY P53396 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3491958 0.88 KMT2A (0.54) MEN1KMT2ANR3C1NR3C2PGR
SCHEMBL3490784 0.85 HPGD (0.47) MEN1KMT2ANR3C1NR3C2PGR
SCHEMBL3490963 0.85 KMT2A (0.50) MEN1KMT2ANR3C1NR3C2PGR
SCHEMBL9215811 0.84 NR3C1 (0.44) MEN1KMT2ANR3C1NR3C2PGR
SCHEMBL3489252 0.84 MEN1 (0.54) MEN1KMT2ANR3C1NR3C2PGR
SCHEMBL3490906 0.82 CA2 (0.53) MEN1KMT2ANR3C1NR3C2PGR
SCHEMBL9272679 0.81 NR3C1 (0.48) MEN1KMT2ANR3C1NR3C2PGR
SCHEMBL3491178 0.81 LMNA (0.52) MEN1KMT2ANR3C1NR3C2PGR
SCHEMBL3488511 0.81 CA12 (0.52) MEN1KMT2ANR3C1NR3C2PGR
SCHEMBL3488631 0.79 KMT2A (0.52) MEN1KMT2ANR3C1NR3C2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D MEN1 4200/4885KMT2A 4557/4885NR3C1 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.